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ABSTRACT
CRISPR/Cas9 technology was used to abrogate p210 oncoprotein expression in 
the Boff-p210 cell line, a pro-B line derived from interlukin-3-dependent Baf/3, that 
shows IL-3-independence arising from the constitutive expression of BCR-ABL p210. 
Using this approach, pools of Boff-p210-edited cells and single edited cell-derived 
clones were obtained and functionally studied in vitro. The loss of p210 expression 
in Boff-p210 cells resulted in the loss of ability to grow in the absence of IL-3, as the 
Baf/3 parental line, showing significantly increased apoptosis levels. Notably, in a 
single edited cell-derived clone carrying a frame-shift mutation that prevents p210 
oncoprotein expression, the effects were even more drastic, resulting in cell death. 
These edited cells were injected subcutaneously in immunosuppressed mice and 
tumor growth was followed for three weeks. BCR/ABL-edited cells developed smaller 
tumors than those originating from unedited Boff-p210 parental cells. Interestingly, 
the single edited cell-derived clone was unable to develop tumors, similar to what is 
observed with the parental Baf/3 cell line.
CRISPR/Cas9 genomic editing technology allows the ablation of the BCR/
ABL fusion gene, causing an absence of oncoprotein expression, and blocking its 
tumorigenic effects in vitro and in the in vivo xenograft model of CML. The future 
application of this approach in in vivo models of CML will allow us to more accurately 
assess the value of CRISPR/Cas9 technology as a new therapeutic tool that overcomes 
resistance to the usual treatments for CML patients.
INTRODUCTION
Fusion proteins resulting from chromosomal 
rearrangements are known to drive the pathogenesis 
of a variety of hematological neoplasms such as 
chronic myeloid leukemia (CML). CML is a malignant 
myeloproliferative disorder driven by hematopoietic stem 
cells that acquire a reciprocal translocation between the 
long arms of chromosomes 9 and 22: t(9;22)(q34;q11) 
[1–3]. This translocation generates the BCR-ABL 
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oncogenic fusion protein, which harbors constitutive 
tyrosine kinase activity. The characteristic expression of 
this oncoprotein transforms the hematopoietic progenitor 
cells by activating downstream signaling proteins that 
increase cell survival and proliferation [4].
CML treatments are based predominantly on the use 
of tyrosine kinase inhibitors (TKI), especially Imatinib 
mesylate, which have been highly effective at increasing 
the life expectancy of CML patients in recent decades. 
However, CML eradication is still hindered by the 
emergence of TKI resistant cells [5–7]. The mechanisms 
of Imatinib resistance can be BCR-ABL-dependent 
(gene amplification or point mutations) or BCR-ABL-
independent [8]. A definitive and effective therapeutic 
strategy is therefore still needed for these patients [9]. 
Recently, Clustered Regularly Interspaced Short 
Palindromic Repeats (CRISPR)/Cas9 technology has 
initiated a new era of genome editing by overcoming 
the limitations of earlier methods [10, 11] that are 
inefficient, time-consuming and labor-intensive processes, 
hindering their general application [12, 13]. The CRISPR/
Cas9 system has been widely used to generate genetic 
mutations in human cells [14–18] and to correct mutated 
genes [19–22]. The CRISPR/Cas9 system has created 
new possibilities for modeling diseases in vitro and 
in vivo, but few studies of CRISPR/Cas9 have explored the 
possibility of editing or correcting fusion genes resulting 
from chromosomal translocations [23–25].
BCR/ABL fusion, which is responsible for CML 
pathogenesis, is an ideal target for CRISPR-Cas9-
mediated gene therapy. Moreover, the CRISPR/Cas9 
system has been overwhelmingly adopted as a powerful 
tool for creating in vivo and in vitro models and new 
therapeutic opportunities for treating human diseases, 
including hematological conditions [26]. Thus, the 
present study shows a CRISPR-Cas9 application for 
truncating the specific BCR-ABL fusion (p210) at the 
genetic level in a cellular model. In addition, functional 
studies were performed to assess the effects of p210 
on cell cycle and apoptosis. In vivo experiments were 
carried out to determine whether its tumorigenic capacity 
was also blocked by the use of mouse xenografts.  To 
our knowledge, this is the first time that? CRISPR/Cas9 
genomic editing system has been used to modify the BCR/
ABL fusion gene successfully preventing its possible 
oncogenic effects. 
RESULTS
The CRISPR/CAS9 system efficiently and 
specifically disrupts the human oncogene BCR/
ABL fusion in an oncogene-dependent cell line
Boff-p210 is an oncogene-dependent cell line in 
which the expression of the human BCR/ABL oncogenic 
fusion confers the ability to survive and proliferate in the 
absence of IL-3 [27]. Cell cycle analysis of Boff-p210 
cultured in the absence of IL-3 confirmed this capacity, 
in contrast to the Baf/3 un-manipulated parental cell 
line, which needs IL-3 to survive and proliferate [28]. 
The Boff-p210 genome was edited using CRISPR-Cas9 
technology to truncate the BCR/ABL oncogene and 
inactivate its malignant potential.
To assess human gene editing using CRISPR/
Cas9 technology in a p210 oncogene-dependent cell 
line, Boff-p210 cells were transduced with a lentivirus 
expressing a constitutive Cas9, thereby establishing the 
Boff-p210 Cas9 cell line. Cas9 nuclease activity was then 
assessed by transducing Boff-p210 Cas9 and its parental 
cell line with a plasmid encoding both GFP and the sgRNA 
against GFP [29]. After ten days, FACS analysis showed, 
upon transduction with this vector, an ~80% reduction in 
the frequency of GFP-positive cells in the active Cas9-
expressing cell line compared with Boff-p210 parental 
cells (Figure 1A), indicating an efficient expression of 
active Cas9 nuclease in Boff-p210 Cas9 cells.
Three custom-designed single guide RNAs 
(sgRNAs) were used to genetically inactivate the BCR/
ABL oncogene. These specific sgRNAs direct Cas9 to 
the BCR/ABL fusion sequence (Bcr-Abl sgRNA) or to 
the Abelson tyrosine kinase sequence (Tk-Abl 1 sgRNA 
and Tk-Abl 2 sgRNA), 40 nucleotides downstream of 
the fusion point (Figure 1B). Three individual lentiviral 
infection assays were performed with each sgRNA to 
generate three different Boff-p210 clones with the edited 
BCR/ABL oncogene, establishing three edited pools of 
Boff-p210 Cas9 cells.
Sanger sequencing showed the presence of indel 
mutations at the expected locations in all the CRISPR-
Cas9 assays with each p210 sgRNA, while no changes 
were observed with mock sgRNA (Figure 2A). Tracking 
of Indels by Decomposition (TIDE) analysis identified 
BCR-ABL sgRNA as the most efficient sgRNA of those 
tested, with 85% of the Boff-p210 Cas9 cell pool edited 
(Bcr-Abl-EP hereafter) (Figure 2B, Table 1). Likewise, the 
algorithm predicted different patterns of genome repair, 
mainly deletions in the 11 bases adjacent to the cleavage 
point. The most frequently predicted mutations were an 
8-bp deletion (18.5%), a 1-bp insertion (17.5%), an 11-bp 
deletion (10.2%) and a 1-bp deletion (9.1%) (Figure 2B, 
Table 1).
Similar indels were obtained with the TK-Ab l 1 
and TK-Abl 2 sgRNAs, although the overall predicted 
editing efficiencies (54.6% and 68.8%, respectively) 
were lower than that of Bcr-Abl sgRNA (Table 1). 
Thus, Bcr-Abl sgRNA was selected to confirm the 
indel mutations generated by the CRISPR/Cas9 
system. Target DNA from the Bcr-Abl-EP cells was 
subcloned by PCR. Colonies were sequenced by the 
Sanger method to confirm that the mutations carried 
by the clones corresponded to the alterations predicted 
by the TIDE algorithm: 1-bp insertion, 1-bp or 8-bp 
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Figure 1: (A) Generation of the Boff-p210 Cas9 cell line. (Left panel) FACS plots showing the lower frequency of GFP-positive cells 
in Cas9-expressing cells compared with parental cells, both transduced with pXPR011. (Right panel) Quantification of GFP expression (mean 
± SD). (B) Schematic representation of BCR/ABL fusion transgene and the sequences of sgRNAs for editing. Schematic representation of 
the BCR/ABL fusion transgene, and the sequences of three sgRNAs designed to edit BCR/ABL. One of them, Bcr-Abl sgRNA (highlighted in 
the red box) had 10 bp complementary to the BCR sequence and 10 bp complementary to the ABL gene, providing high specificity with the 
fusion gene sequence. Tk-Abl 1 and Tk-Abl 2 sgRNA were complementary to the ABL sequence. The arrowhead indicates the expected Cas9 
cleavage site. PAM (highlighted in the black box) is the protospacer-adjacent motif required for Cas9 nuclease activity.
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deletions (Figure 2C). These findings suggest that 
these mutations are frequently generated when the 
cell repairs the Cas9-induced cleavage. Moreover, 
next-generation sequencing (NGS) was performed to 
sequence the target region of the Bcr-Abl-EP cells 
(coverage = 3386X). Several indels were detected 
around the expected Cas9 cleavage point (Figure 2D). 
The most frequent indels (> 5%) were frame-shift 
mutations producing a stop codon, except for the TTC-
3bp-deletion (52 reads), which caused the loss of a 
leucine, but did not alter the downstream reading frame 
(Figure 2D). Therefore, most of the edited Bcr-Abl-EP 
cells showed mutations that produce truncated p210 
oncoprotein (Figure 2D).
It is of note that no altered sequences were found 
in any of the top five potential off-target genes of Bcr-
Abl sgRNA (Table 2), suggesting that the activity of 
the CRISPR/Cas9 system designed in our experimental 
procedures is highly specific.
Establishment of a single cell derived-cell line 
carriying a specific CRISPR/CAS9-mediated 
mutation in the BCR/ABL oncogene 
To generate a clone of Boff-p210 cells with 
truncated BCR-ABL oncoprotein, single cells from 
the Bcr-Abl-EP cell line, were sorted by FACS. 41 
single-cell clones were analyzed by Sanger sequencing, 
which revealed that most of them (32/41) had an edited 
sequence (Supplementary Table 1). Four of these 
32 clones, showing indel mutations that generated a 
premature stop codon near the Cas9 cleavage point, 
were choose to functional analysis (Supplementary 
Figure 2A).  One of them (Clone 1), which carried an 
8-bp deletion at the expected cleavage point, was selected 
to establish the cell line known as Bcr-Abl-SC (single 
edited cell-derived Boff-p210-Cas9), whose frame-
shift mutation was predicted by the TIDE algorithm 
and confirmed by both PCR-subcloning and NGS 
(Figure 2E). In silico analysis of the mutation in clone 1 
resulted in the generation of a stop codon downstream of 
the Cas9 cleavage point, leading to the alteration of the 
open reading frame and the subsequently premature end 
of translation (Figure 2E).
Obliteration of the BCR/ABL oncogene by 
CRISPR-CAS9 in the BOFF-P210 cell line leads 
to an absence of the oncogenic protein
To confirm that the CRISPR-Cas9 system efficiently 
truncates BCR/ABL oncogene, the presence of the BCR-
ABL oncoprotein was tested by western blot analysis. A 
single band, corresponding to the ABL protein (140 kDa), 
was detected in Baf/3 (Figure 3A), while Boff-p210 also 
showed a 210-kDa band corresponding to a BCR-ABL 
fusion. No changes were observed in either BCR-ABL 
or ABL expression in pools of edited cells (Figure 3A). 
Similar results were obtained for the TK-Abl sgRNAs cell 
lines (Supplementary Figure 1A). In contrast, BCR-ABL 
protein expression was undetectable in the Bcr-Abl-SC 
cells (Figure 3A, Supplementary Figure 2B).  
In vitro ablation of BCR/ABL by the CRISPR/
CAS9 system in tumorigenic p210 cells induces 
cell cycle arrest and impairs survival
To study the consequences of in vitro obliteration 
of the BCR/ABL oncogene by the CRISPR-Cas9 system, 
the processes of cell-cycle progression and apoptosis 
were analyzed in Boff-p210-edited cells in the presence 
or absence of IL-3 for 4 days.
Annexin V and PI labeling were used to measure 
apoptosis in Boff-p210 cells by flow cytometry after 
4 days in culture in the presence or absence of IL-3 
(Figure 3B). We simultaneously analyzed the distribution 
of the cells in the different cell cycle phases by 
permeabilization followed by PI staining (Figure 3C). 
Non-tumorigenic Baf/3 cells rapidly died after 4 days 
in IL-3-withdrawn medium (Figure 3A). After 4 days 
of IL-3 deprivation, 73.3% of the Baf/f3 cells showed 
annexin V staining (Figure 3B, 3D), and there was clear 
evidence of oligonucleosomal DNA degradation (subG0 
DNA content), characteristic of apoptosis (Figure 3C). 
In contrast, only 10–20% of the Boff-p210 or Boff-p210 
Table 1: TIDE algorithm predicted indels induced by each sgRNA
Guide Edition efficiency TIDE Predicted Indels
Bcr-Abl sgRNA 85%
+1 bp (17.5%), –1 bp (9.1%), –2 bp (4.8%)
–3 bp (3.4%), –4 bp (6%), –6 bp (1.8%), 
–8 bp (18.9%), –11 bp (10.2%), –18 bp (5.1%)
TK-ABL 1 sgRNA 54,6% +1 bp (14.9%), –1 bp (8%)–2 bp (5.2%), –10 bp (17.6%)
TK-ABL 2 sgRNA 68,8% +1 bp (30.8%), –1 bp (5.9%), –2 bp (4.8%), –4 bp (15.2%), –14 bp (5.1%)
Mock sgRNA 0%
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Figure 2: Genome editing of BCR/ABL in the Boff-P210 cell line. (A) Sanger sequencing of the BCR/ABL fusion region in 
Boff-p210 cells. The Boff-p210 cells expressing mock sgRNA, used as a control, had a wild type sequence, while cells expressing Bcr-
Abl sgRNA (Bcr-Abl-EP), Tk-Abl1 sgRNA (Tk-Abl1-EP) and Tk-Abl2 sgRNA (Tk-Abl1-EP) showed a mixture of sequences around 
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Cas9 mock sgRNA cells, growing with or without IL-3, 
were positive for annexin V staining (Figure 3B, 3D). 
Similarly, no differences in the distribution of the cell 
cycle phases were observed in Boff-p210 and mock cells 
in the presence or absence of IL-3 (Figure 3C), with no 
evidence of cells in sub-G0. However, withdrawal of 
IL-3 in Bcr-Abl-EP cell cultures resulted in increased 
annexin V staining (7.89% in medium with IL-3; 38.04% 
in the absence of IL3), indicating that edited cells are IL3-
dependent (Figure 3B, 3D).  Accordingly, we observed a 
decrease in the G1, S and G2/M phases of the cell cycle 
in Bcr-Abl-EP cells in the absence of IL-3, while the 
presence of IL-3 maintained the cell viability of these 
cells. Boff-p210 and non-edited Boff-p210 cells (mock 
sgRNA assay) yielded similar results in the distribution 
of the cell cycle phases with or without IL3-conditioned 
medium (Figure 3C). A similar effect was observed in TK-
ABL1-EP and TK-ABL2-EP cells in the absence of IL-3 
(Supplementary Figure 1B).
To confirm that the loss of ability to grow in the 
absence of IL-3 observed in the pool of edited cells was 
due solely to the disruption of the BCR/ABL transgene, 
we assessed the effect of IL-3 withdrawal in an edited cell 
line derived from a single cell (Bcr-Abl-SC cells). Like 
control mock and Bcr-Abl-EP cells, Bcr-Abl-SC cells 
showed low expression of annexin V (11.23% of cells) 
and high viability in the presence of IL-3 (Figure 3B, 3C, 
3D). However, after 4 days in IL-3-deprived culture, most 
cells (97.7%) showed a high level of annexin V staining 
(Figure 3B, 3D), accompanied by fragmented DNA 
(Figure 3C). The dramatic effect observed in the Bcr-
Abl-SC cell line, similar to that of Baf/3 cells, suggests 
that there is a complete lack of BCR-ABL functional 
oncoprotein. These results were confirmed in three clones 
derived from a single-edited cell carrying a truncated 
BCR/ABL sequence in which IL-3 withdrawal produced a 
similar drastic effect (Supplementary Figure 2C).
CRISPR-CAS9 impairs the tumorigenic capacity 
of edited Boff-p210 selected cells 
In order to determine the effects of Bcr/Abl 
oncogene disruption in vivo, the flanks of CB17C SCID 
mice were subcutaneously injected with Baf/3, Boff-p210, 
Bcr-Abl-EP cells, and Boff-p210 Cas9 mock sgRNA 
(Boff-p210 mock) cells. Mice injected with Boff-p210 cells 
and Boff-p210 mock cells, developed similar detectable 
tumors (mean mass: 663 mg and 445 mg respectively). In 
contrast, mice injected with Bcr-Abl-EP cells gave rise to 
significantly smaller (around 60%) subcutaneous tumors 
than those produced by the non-edited cells (mean mass: 
172 mg; Figure 4A and 4B). As expected, Baf/3 cells 
showed no tumor growth in this period.
Bcr-Abl-SC cells carrying an 8-bp deletion (clone 1, 
Supplementary Figure 2) were selected to test their 
tumorigenic capacity by injection into the flank of CB17C 
SCID mice. Non-edited Boff-p210 cells and Baf/3 cells 
were also injected as controls. 24 days post-injection, 
tumor growth was clearly detected in mice injected with 
non-edited Boff-p210 cells. Conversely, no tumor growth 
was observed in mice injected with cells derived from the 
single-edited cell line, or with Baf/3 cells (Figure 4A).
DISCUSSION
In this study, we have explored the ability use of the 
CRISPR/Cas9 technology to obliterate BCR-ABL fusion 
in order to determine its impact on the leukemic processes 
in in vitro and in xenograft models of CML. The CRISPR/
Cas9 system has recently emerged as a powerful genome 
editing tool [14, 30]. Cas9 nuclease from Streptococcus 
pyogenes can be guided by means of simple base-pair 
complementarity between the first 20 nucleotides of an 
engineered sgRNA and a target genomic DNA sequence 
of interest [31, 32]. Recently, this technology has been 
used for gene correction of point mutations in cells 
[20, 21, 33]. However, to our knowledge, this is the first 
study in which CRISPR/Cas9 has been used to prevent 
the tumorigenic ability of an oncogenic fusion, such BCR/
ABL, by inducing frame-shift mutations. 
It is well known that the crucial genetic event in 
CML development is the generation of a t(9;22)(q34;q11) 
reciprocal chromosomal translocation [34], resulting 
mainly in the generation of the BCR-ABL (p210) 
oncoprotein with a constitutive kinase activity [35–37]. 
Herein, the tumorigenic Boff-p210 cell line is used as a 
cellular model, which is particularly suitable for BCR-
ABL assays. This is an interleukin 3- (IL-3) independent 
cell line derived from the Baf/3 hematopoietic cell line 
[38]. Boff-p210 expresses the BCR-ABLp210 oncogene as 
a tetracycline-regulated transgene and can be genetically 
modified, expanded and then re-administered into 
immunocompromised mice. In the absence of tetracycline 
or doxycycline, BCR/ABL expression is constitutive, 
the expected Cas9 cleavage point. (B) TIDE decomposition algorithm analysis of the edited sequence in Bcr-Abl-EP cells, showing 
high editing efficiency at the expected cleavage point. The lower panel illustrates the aberrant sequence signal in Boff-p210 cells (black) 
and Boff-p210-edited cells (green) and the expected cleavage site (vertical dotted line). (C) DNA sequences of DNA post-PCR cloning 
colonies of Boff-p210-edited cell DNA. We compare three induced mutations with the original sequence. (D) Next-generation sequencing 
of the transgene target region.  The upper panel shows the percentages of each base pair in the sequenced region. The lower panel shows 
commonly sequenced variants for CRISPR-targeted Bcr/Abl transgene in Boff-p210 cells. The sgRNA-target site is displayed in red, the 
PAM sequence as text underlined in red, and the cleavage site is indicated by a triangle. The number of reads per variant and the predicted 
effect of the mutation are shown. (E) In silico analysis of single cell-derived clone. Clone 1 showed a 8 bp deletion resulting in a stop codon 
and in a premature end of translation. It was selected to establish the Bcr-Abl-SC cell line.   
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Figure 3: Functional analysis of Boff-p210-edited cells. (A) Western blot analysis of BCR-ABL expression. Abl expression 
(140 kDa) was observed in all cells.  A 210 kDa band, corresponding BCR-ABL expression was observed in unedited Boff-p210 cells 
(parental and sgRNA mock controls) and in Bcr-Abl-EP cells. In contrast, Bcr-Abl-SC and Baf/3 cells showed no expression of BCR-ABL. 
(B) Annexin V/propidium iodide labeling of Boff-p210 cells after four days in culture in the presence or absence of IL-3. Unedited and 
mock sgRNA-expressing cells showed IL-3-independent growth. Baf/3 as Bcr-Abl-EP cells showed greater annexin V labeling after IL-3 
withdrawal. This effect was stronger in cell lines derived from a single-edited cell. (C) Flow cytometric analysis of Bcr-Abl-EP cells. No 
changes were observed in the cell cycle phases of Boff-p210 or the mock cells, grown with or without IL-3. High frequencies of cells in the 
subG0 phase were found in the single edit derived-cells cultured without IL-3, as in Baf/3 cells. (D) Quantification of annexin V labeling 
(Left graph, represented as mean ± SEM; ***p < 0.001) and percentage of Boff-p210-positive cells (right graph).
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Table 2: Analysis of the genomic potential off-targets of Bcr-Abl sgRNA
Gene Annotation Target Forward Reverse
Rcor1 NM_198023 GGAAATCACAAGCCCTTCAGCAG ATGGCAGCTCTCCCAATCAACA TACAAGCACCAGGTACAATGA
Epg5 NM_001195633 AGTGTTGAATAACCCTTCAGGGG CAGTAGCAGTGTTGCCCTCCA CACACCTTCTCTTAGTCTATGG
Gimap7 NM_146167 AGAACTCAAAGGCCCTGCAGGAG CTAAGCAACATGTGGACCACT GGAGCTGAAGGGAGTTAGGG
Zfp457 NM_001003666 AGTGTACAAAAGCTCTTCAGTGG GCGACTAAGATGGTTTCAATAG GCACAGCACCTCAAGGTCAG
Alg10b NM_001033441 AGAGCCCACAACCCCTTCAGCGG AGTGCTCCTAAGGGGCTTAGT GAAGTAAGCGGCATTGCTTATAG
Figure 4: In vivo effects of CRISPR-mediated editing of the BCR/ABL oncogene. (A) Tumor growth (mm3) over the 24 days 
following subcutaneous cell injection. Similar tumor growth was observed in Boff-p210 (grey bars) and Boff-p210 Cas9 mock sgRNA 
(black dots line) injected cells. Tumors formed by Bcr-Abl-EP cells (black squares line) were half the size of those induced previously. 
Tumor growth was observed when the single edited cell-derived cells were injected (grey dotted line), as well Baf/3 cells (dark grey bars). 
The plot shows medians and ranges; ***p < 0.001). (B) After 24 days, mice were sacrificed and their tumor mass measured. The final tumor 
mass was reduced by half in the case of the edited pool cells (black squares), relative to controls (black dots). Bcr-Abl-SC (grey dots) and 
Baf/3 (black triangles) cells were unable to form a subcutaneous tumor. The plot shows medians and ranges; **p < 0.05). (C) External 
appearance of mice and developed tumors 24 days after subcutaneous cell injection.
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and confers on Boff-210 cells the ability to survive and 
proliferate in the absence of IL-3 [39].
A Boff-p210 cell line expressing constitutively 
active Cas9 was generated to genetically inactivate human 
BCR/ABL oncogenes, thereby to avoid its pathological 
effect on the Boff-p210 cell line. Three specific sgRNAs 
against the BCR/ABL fusion gene were designed as RNA 
guides for Cas9. One of them drives Cas9 nuclease against 
the BCR/ABL junction sequence and the other two drive it 
against the ABL tyrosine kinase sequence. The CRISPR-
Cas9 system was highly effective at inducing indels in 
their target sequences with all the sgRNAs used. Notably, 
Bcr-Abl sgRNA was the most efficient, involving up to 
80% of the edited cells. 
Since CRISPR/Cas9 nuclease can induce off-
target cleavages, due to unspecific recognition of non-
target sequences [40], the integrity of the main off-target 
sequences was tested. It is worth pointing out that no off-
target sequences were observed in any of the edited pools 
of cells. These findings suggest that the CRISPR/Cas9 
system is highly specific, as has been demonstrated by 
earlier whole-genome sequencing studies [41–43].
The effects of the constitutive BCR/ABL activity are 
pleiotropic and promote leukemogenesis by acquisition of 
tumor abilities. These abilities include the increase of cell 
survival [4], the avoidance of apoptosis [39, 44, 45] and 
the promotion of genomic instability by downregulation of 
DNA-repair mechanisms [46, 47]. In this cellular model, 
the expression of BCR-ABL oncoprotein induces IL-3-
independent proliferation and survival, while Baf/3 cells 
require IL-3 to survive and proliferate (Figure 3B–3D). 
To study the oncogene-disruption effect in this cellular 
model, CRISPR-Cas9 edition assays were performed. 
The CRISPR-Cas9 system efficiently induced different 
mutations at the expected cleavage expected point, 
giving rise to a cellular pool with several altered BCR/
ABL sequences. A significant increase in cell death 
was observed in Bcr-Abl-EP cells in the absence of 
IL- 3, compared with Boff-p210 parental cells or mock 
Boff-p210 cells. However, a massive cell death was not 
observed in Bcr-Abl-EP cells, indicating the presence of 
edited cells with survival capacity in the absence of IL-3. 
This finding was corroborated by the fact that Bcr-Abl-
EP did not show any significant variations in the level of 
p210 expression as shown by western blot analysis. As 
confirmed by NGS, the CRISPR-Cas9 system induced 
several different indel mutations in our edited cell lines. 
Some of them were frame-shift mutations that resulted in 
truncated proteins, whereas others generated a gain/loss of 
amino acids that gave rise to a functional protein. These 
functional repaired p210 proteins could protect cells from 
apoptosis induced by IL-3 withdrawal, promoting the cell 
survival of several clones. This result is consistent with 
previous reports about the antiapoptotic effect of the BCR/
ABL [44, 45]. To avoid this drawback, a single cell with 
a specific edited sequence of BCR/ABL was isolated from 
the edited pool. In particular, a specific single-cell clone 
with an 8-bp deletion at the cleavage point was selected for 
further experiments. The selected cell clone had an edited 
p210 sequence, which gave rise to a premature translation 
end. In fact, no BCR-ABL oncoprotein expression was 
observed by western blot. Interestingly, this single edited 
cell-derived clone showed the highest level of apoptosis 
(more than 97% of cells) when it grew in the absence of 
IL-3, compared with that observed in cells that did not 
express p210.
To further test the tumorigenic capability of 
the BCR-ABL-edited cells, the xenograft model was 
generated by injecting these edited cells into mice. In all 
cases, the pool of Boff-p210-edited cells gave rise to a 
subcutaneous tumor 24 days post-injection. These findings 
indicate that cells with functional BCR-ABL oncoproteins 
maintain their tumorigenic capabilities. In contrast, cell 
clones derived from a single-edited cell were unable to 
induce tumors in all cases. This result demonstrates that 
CRISPR-Cas9 could efficiently prevent the tumorigenic 
potential of the p210 oncoprotein.
Despite major improvements in therapeutic 
strategies in patients with CML in recent decades, as a 
consequence of the use of tyrosine kinase inhibitors, 
eradication of CML remains a challenge because of the 
emergence of drug resistance. In the context of stem cell 
transplantation [48], the use of CRISPR-Cas9 technology 
could be a promising new therapeutic option for CML 
patients who have developed tyrosine-kinase resistance. 
Bone marrow leukemic stem cells could be edited by 
CRISPR-Cas9 technology to truncate BCRL/ABL fusions, 
and truncated cells specifically selected before infusion. 
However, the fact that of sgRNAs can tolerate certain 
mismatches and that Cas9 is integrated and constantly 
produced represent the key limit of this technology. The 
use of integrase-deficient lentivirus vectors or Cas9-guide 
RNA ribonucleoprotein (RNP) complexes into primary 
cells, could represent a safety advantage in human therapy 
[49–51]. Further studies with human primary cells should 
be performed to test this hypothesis.
Our study is the first step towards providing proof-
of-principle for genome editing of the main genetic event 
in CML patients. In summary, this is the first report 
describing the use of CRISPR/Cas9 genome editing to 
completely truncate human BCR-ABL oncoprotein fusion 
in order to prevent its tumorigenic abilities in an in vitro 
as well as in an in vivo CML model.
MATERIALS AND METHODS
Cell lines and culture conditions
Boff-p210 is a murine interleukin 3 (IL3) 
-independent cell line derived from the hematopoietic cell 
line Baf/3 [38] that expresses BCR/ABL as a tetracycline-
regulated transgene (BCR/ABL expression is constitutive 
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in the absence of tetracycline or doxycycline) [52–54]. 
Boff-p210 was maintained in Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Life Technologies) supplemented 
with 10% fetal bovine serum (FBS) and 1% of penicillin/
streptomycin (Life Technologies) in 5% CO2 at 37°C. 
IL-3-dependent Baf/3 cells, used as a parental cell line, 
were grown in the same medium supplemented with 10% 
WEHI-3-conditioned medium as a source of IL-3. 
HEK 293T cells were used for lentivirus production. 
They were maintained in RPMI 1640 (Life Technologies) 
supplemented with 10% FBS and 1% penicillin/
streptomycin (Life Technologies).
Lentiviral constructs, sgRNA design and sgRNA 
cloning
The constitutive Cas9 expression vector (plasmid 
LentiCas9-Blast, a gift from Feng Zhang, Addgene 
plasmid # 52962)[55] was used to generate the Boff-p210 
cell line with stable Cas9 expression.
pLKO5.sgRNA.EFS.GFP (Addgene plasmid # 
57822) [56] containing the coding sequence of GFP and a 
cloning site for sgRNA sequence was digested with Esp3I 
(BsmBI) (NEB). To clone the sgRNAs into the pLKO5 
vector, two complementary oligos for each sgRNA 
were designed including two 4bp-overhang sequences 
(Table 3). The sgRNAs sequences were designed with 
the Broad Institute CRISPR designs software (http://
www.broadinstitute.org/rnai/public/analysis-tools/sgrna-
design). One sgRNA (Bcr-Abl sgRNA) was designed 
to specifically target the fusion junction sequence. To 
control for variability in targeting efficiency and potential 
off-targets effects, two sgRNAs were designed to target 
the ABL tyrosine kinase sequence (Tk-Abl1 sgRNA and 
Tk-Abl2 sgRNA) (Figure 1B). An sgRNA designed not to 
target the genome was used as a negative control (mock). 
The two complementary oligos were denatured at 95°C 
for 5 min, ramp cooled to 25°C over a period of 45 min 
to allow annealing, and finally ligated with the linearized 
pLKO5. Competent cells were transformed with 2 μl of the 
ligated plasmid, and single colonies were expanded before 
to plasmid extraction using a QIAprep Spin Maxiprep kit 
(Qiagen). The correct insertion of the sgRNA sequences 
was confirmed by using Sanger sequencing.
Cas9 activity was tested using a previously reported 
system based on the pXPR-011 plasmid (a gift from John 
Doench and David Root; Addgene plasmid #59702) which 
delivers GFP and sgRNA targeting GFP [29].
Lentiviral production and cell transduction
Lentiviral particles were produced by transient 
transfection of HEK 293T cells using Lipofectamine 
2000® (Life Technologies). Viral constructs were co-
transfected with pMD2.G (Addgene plasmid 12259) 
and psPAX2 (Addgene plasmid 12260) (both kindly 
provided by Didier Trono, EPFL, Lausanne, Switzerland). 
Lentiviral particles were collected at 24 and 48 h, and, 
finally, were concentrated using Lenti-X concentrator® 
(Clontech). Cells were infected in 24-well plate format, 
with each well containing 2 × 105 cells, cultured in media 
supplemented with 4 µg/mL polybrene. 
Cas9 activity assay system
To obtain stable Boff-p210 cells expressing 
Cas9, lentiviral particles containing LentiCas9-Blast, 
plasmid-expressing Cas9 and blasticidine resistance (a 
gift from Feng Zhang, Addgene plasmid # 52962)[55], 
were transduced into Boff-p210 cells and selected by 
blasticidine (10 µg/µl), over ten days.  
Cas9 activity was assessed using the Cas9-activity 
vector as previously reported [29]. The Cas9-expressing 
Boff-p210 cell line and its corresponding parental Boff-p210 
cell line were transduced with plasmid pXPR-011, encoding 
both GFP and sgRNA against GFP (a gift from John Doench 
and David Root; Addgene plasmid # 59702) [29]. 48 h post-
infection, 2 µg/mL puromycin was added and cells were 
selected for three days. GFP-positive cells from both cell lines 
were analyzed by BD FACScalibur ten days post-infection. 
Sequencing of sgRNA targets sites
Genomic DNA was extracted using the QIAamp 
DNA Micro Kit (Qiagen) following the manufacturer’s 
protocol. To amplify the region of the BCR-ABL fusion, 
PCR was performed using the following primers: forward 
5′- TCGTGTGTGAAACTCCAGACTGTC – 3′ and 
reverse 5′- TTGGGCTTCACACCATTCCCC – 3′. PCR 
products were purified using a High Pure PCR Product 
Purification Kit (Roche) and were sequenced by the Sanger 
method using each forward and reverse PCR primers.
The editing efficiency of the sgRNAs and the potential 
induced mutations were assessed using Tracking of Indels by 
Decomposition (TIDE) software (https://tide-calculator.nki.nl; 
Netherlands Cancer Institute), which only required two Sanger 
sequencing runs from wild-type cells and mutated cells.
To identify specifically the different generated 
mutations, total DNA of Cas9-edited cells were PCR-
amplified, subcloned and transformed in bacteria. DNA from 
single clones were extracted with a QIAprep Spin Miniprep 
Kit (Qiagen) and sequenced by Sanger sequencing. 
In parallel, Next Generation Sequencing (NGS) 
technology was employed with the same Sanger primers 
with the corresponding adapters added, to read each 
edited sequence individually. The amplicon libraries were 
sequenced on the GS Junior platform (454 Life Sciences, 
Roche, Branford, CT, USA) [57].
Western blot 
BCR-ABL protein expression was assessed by 
SDS-PAGE and western blotting using a mouse anti-
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ABL antibody (1:1000; SC-23, Santa Cruz). Horseradish 
peroxidase-conjugated α-mouse antibody (1:10000; 
NA931V, GE Healthcare) was used as a secondary 
antibody. Antibodies were detected using ECLTM Western 
Blotting Detection Reagents (RPN2209, GE Healthcare).
Flow cytometry analysis and cell sorting for 
Cas9-mediated editing and for isolating single 
edited cell-derived clone
72 hours after infection by lentivirus-expressing 
sgRNAs with GFP of Boff-p210 Cas9 cell lines, GFP-
positive cells were selected by fluorescence-activated 
cell sorting (FACS) using FACS Aria (BD Biosciences), 
establishing the cell lines known as  Bcr-Abl-EP, Tk-Abl1-
EP and Tk-Abl2-EP. Single-cells were seeded in 96-well 
plate by FACS, establishing four clones with frame-shift 
mutations that disrupt the BCR/ABL sequence. Clone 1 was 
chosen to establish the cell line known as Bcr-Abl-SC.
Off-target sequence analysis
To investigate off-target cleavage potentially 
generated by Cas9 in Bcr-Abl-EP and Bcr-Abl-SC cells, 
the top five off-target sites (obtained from the crispr.
mit.edu website) were analyzed by PCR and Sanger 
sequencing, just before to start the functional and 
xenograft experiments. The primers used to amplify the 
top five predicted off-targets regions are described in 
Table 2. PCR products were purified using a High Pure 
PCR Product Purification Kit (Roche) and were sequenced 
using each forward and reverse PCR primers.  
Apoptosis and cell cycle analysis.
Apoptosis was measured by flow cytometry with an 
annexin V-Dy634 apoptosis detection kit (ANXVVKDY, 
Immunostep) following the manufacturer’s instructions. 
Briefly, 5 × 105 cells were collected and washed twice in 
PBS, and labeled with annexin V-DY-634 and non-vital 
dye propidium iodide (PI), allowing the discrimination of 
living-intact cells (annexin-negative, PI-negative), early 
apoptotic cells (annexin-positive, PI-negative) and late 
apoptotic or necrotic cells (annexin-positive, PI-positive). 
In parallel, cell distribution in the cell cycle phase was also 
analyzed by measuring DNA content (PI labeling after cell 
permeabilization).
Mouse xenograft tumorigenesis
18 four- to five-week-old female CB.17 SCID mice 
(Charles River, Barcelona, Spain) were used (six mice per 
group). Tumor xenografts were induced by subcutaneous 
injection of cell suspensions containing 8 × 106 cells in 
0.2 ml of cellular medium into the mouse flank. 
Cells were counted using a Neubauer chamber 
(VWR) and cellular viability monitored by trypan blue 
staining (Sigma). This study followed the Spanish and 
European Union guidelines for animal experimentation 
(RD 1201/05, RD 53/2013 and 86/609/CEE, respectively). 
The study received prior approval from the Bioethics 
Committee of our institution.
In the first mouse group, Boff-p210 Cas9 mock 
sgRNA cells were injected in the left flank and Bcr-Abl-
EP cells in the right flank; in the second group, Boff-
p210Cas9 mock sgRNA cells were injected in the left 
flank and Bcr-Abl-SC cells in the right flank; and, finally, 
in the third group (controls), Boff-p210 cells were injected 
in the left flank and Baf/3 in the right flank. Tumor 
diameters were measured every 2–3 days with a caliper. 
Tumor volume was calculated as described elsewhere [58] 
by the formula a2bπ/6 (a and b being, respectively, the 
smallest and the biggest diameters). Mice were sacrificed 
by anesthesia overdose 24 days after cell injection, upon 
which the tumors were collected and weighted.
Statistical analysis 
Statistical analysis was performed using GraphPad 
Prism 6 Software (GraphPad Software). Differences in 
annexin V labeling were tested using one-way ANOVA 
and Tukey’s multiple comparisons test. Differences in 
tumor volume over time were tested by two-way ANOVA, 
and Tukey’s multiple comparisons test. Differences 
in median tumor masses were tested by the Kruskal-
Wallis and Mann-Whitney U tests, and Dunn’s multiple 
comparisons test. Statistical significance at values of 
p < 0.05 (**) and p < 0.001 (***) was noted.
Abbreviations
CML: Chronic myeloid leukemia; CRISPR: 
Clustered regularly interspaced short palindromic repeats; 
sgRNA: Single-guide RNA; EP: Edited pool; SC: Single 
edited cell-derived.
Table 3: Oligos designed for each sgRNA
Forward Reverse
Bcr-Abl CACCGAGAGTTCAAAAGCCCTTCAG AAACCTGAAGGGCTTTTGAACTCTC
TK-Abl 1 CACCGAGCCGCTCGTTGGAACTCCA AAACTGGAGTTCCAACGAGCGGCTC
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